A New CAR-T Cell Approach for Synovial Sarcoma That Does Not Require HLA Matching

A new preclinical study published in Biomedicine and Pharmacotherapy by Tomohiro Miyazaki, Yudai Murayama, Naoki Oike, and colleagues from the Department of Pediatrics and Division of Orthopedic Surgery at Niigata University Graduate School of Medical and Dental Sciences, Japan, presents early but promising evidence for a CAR-T cell therapy designed for synovial sarcoma that does not require the HLA matching that limits eligibility for currently available TCR-T cell therapies.

The Problem This Research Is Trying to Solve

TCR-engineered T cell therapies, including the FDA-approved Tecelra, have delivered meaningful results in synovial sarcoma. However, these therapies require a specific HLA genotype present in only approximately 30% of the population, leaving at least 70% of patients ineligible. The Niigata University team set out to develop a CAR-T approach that sidesteps this limitation, since CAR-T cells recognize surface antigens without requiring HLA matching.

What NKG2D Is and Why It Is a Promising Target

NKG2D is a receptor on natural killer cells that activates immune responses against cancer cells. It recognizes a family of eight ligands (NKG2DLs) rarely expressed in healthy tissue but commonly found on tumor cells. The researchers confirmed NKG2DL expression across all three synovial sarcoma cell lines tested, and found significantly higher expression in primary tumor tissue compared to adjacent normal tissue. Unlike conventional CAR-T approaches targeting a single antigen, NKG2D-based CARs recognize all eight ligands simultaneously, potentially reducing the risk of tumor cells escaping treatment through antigen loss.

What the Study Found

The team constructed NKG2D-based CAR-T cells and tested them against synovial sarcoma in the laboratory and in mouse models. In laboratory experiments, the NKG2D-CAR-T cells showed significantly stronger anti-tumor activity against all three synovial sarcoma cell lines compared to control T cells, even at very low effector-to-tumor cell ratios. In mouse experiments, the CAR-T cells significantly suppressed tumor growth compared to no treatment and to a non-targeting control, with statistically significant differences in tumor volume by day 28.

Looking Ahead

This study is preclinical and has not yet been tested in humans. Further mechanistic, translational, and safety studies are needed before clinical trials can begin. However, if validated, NKG2D-based CAR-T therapy could represent the first cell therapy for synovial sarcoma that does not require HLA matching, potentially opening treatment to the majority of patients currently ineligible for existing TCR-T approaches. It would also offer a distinct mechanism of action for patients who have not responded to or relapsed after prior T-cell therapy.

For more information, read the original publication. For more information about the Synovial Sarcoma Foundation, please visit our website.